[5-(3,5-Dichlorophenyl)sulfanyl-3-(hydroxymethyl)-1-propan-2-ylpyrazol-4-yl]methanol

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: [5-(3,5-Dichlorophenyl)sulfanyl-3-(hydroxymethyl)-1-propan-2-ylpyrazol-4-yl]methanol
• 化学式: C₁₄H₁₆Cl₂N₂O₂S
• 分子量: 347.3
• InChiKey: ZICBEMJXOXYDGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• EP1385836A2
  申请人：——

  公开号：EP1385836A2

  公开（公告）日：2004-02-04
• PYRAZOLE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1401826B1

  公开（公告）日：2007-03-21
• US6538015B1
  申请人：——

  公开号：US6538015B1

  公开（公告）日：2003-03-25
• [EN] AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS<br/>[FR] SULFONE HYDROXAMATES AROMATIQUES ET LEUR UTILISATION COMME INHIBITEURS DE LA PROTEASE
  申请人：PHARMACIA CORP

  公开号：WO2002092588A2

  公开（公告）日：2002-11-21

  This invention is directed to aromatic sulfone hydroxamates (also known as 'aromatic sulfone hydroxamic acids') and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as 'matrix metalloprotease' or 'MMP') activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
• [EN] PYRAZOLE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS<br/>[FR] DERIVES DE PYRAZOLE UTILISES COMME INHIBITEURS DE LA TRANSCRIPTASE INVERSE DU VIH
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002100853A1

  公开（公告）日：2002-12-19

  The invention is concerned with novel pyrazole derivatives, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula I are inhibitos of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. Consequently the compounds of this invention may be advantageously used as therapeutic agents for HIV mediated process. The invention describes novel compounds of formula I wherein R?1, R2, R3¿ and A are as defined in the description; ethers of compounds of formula I as well as pharmaceutically acceptable salts of the foregoing.